{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:38Z","timestamp":1786988138997,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023J01012"],"award-info":[{"award-number":["2023J01012"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011151","name":"American Academy of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271054"],"award-info":[{"award-number":["82271054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejphar.2025.177820","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T02:30:17Z","timestamp":1749263417000},"page":"177820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database"],"prefix":"10.1016","volume":"1002","author":[{"given":"Shi-Nan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7117-5978","authenticated-orcid":false,"given":"Qian-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ying","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoyue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177820_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/15569527.2022.2052889","article-title":"Ocular adverse effects of bladder medication: a systematic review","volume":"41","author":"Bassi","year":"2022","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.ejphar.2025.177820_bib2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177820_bib3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/pds.2247","article-title":"Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and multi-item gamma poisson shrinker","volume":"21","author":"Berlin","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177820_bib4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1159\/000439490","article-title":"Retinal involvement in a patient with cerebral manifestation of chronic graft-versus-host-disease","volume":"38","author":"Blecha","year":"2015","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.ejphar.2025.177820_bib5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.oret.2023.06.009","article-title":"Detection and management of intraocular inflammation after brolucizumab treatment for neovascular age-related macular degeneration","volume":"7","author":"Bodaghi","year":"2023","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.ejphar.2025.177820_bib6","article-title":"Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide","volume":"36","author":"Bracha","year":"2024","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"10.1016\/j.ejphar.2025.177820_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177820_bib8","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1111\/cns.14195","article-title":"Updated insights on dementia-related risk of sacubitril\/valsartan: a real-world pharmacovigilance analysis","volume":"29","author":"Chen","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejphar.2025.177820_bib9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177820_bib10","series-title":"Auditory and Vestibular Side Effects of FDA-Approved Drugs for Diabetes","first-page":"315","author":"DiSogra","year":"2019"},{"key":"10.1016\/j.ejphar.2025.177820_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/15569527.2015.1072547","article-title":"The short-term and long-term adverse ocular effects of fesoterodine fumarate","volume":"35","author":"Erginturk Acar","year":"2016","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.ejphar.2025.177820_bib12","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.ejphar.2025.177820_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101302","article-title":"Ocular adverse events associated with antibody-drug conjugates used in cancer: focus on pathophysiology and management strategies","volume":"103","author":"Gabison","year":"2024","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ejphar.2025.177820_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2025.01.018","article-title":"Pharmacologic agents used in the assessment or correction of blepharoptosis: a report by the American academy of ophthalmology","author":"Grob","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejphar.2025.177820_bib15","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1167\/iovs.03-1199","article-title":"Stepping up to a new level: effects of blurring vision in the elderly","volume":"45","author":"Heasley","year":"2004","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejphar.2025.177820_bib16","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1167\/iovs.05-0059","article-title":"Falls in older people: effects of age and blurring vision on the dynamics of stepping","volume":"46","author":"Heasley","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejphar.2025.177820_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jclinepi.2021.07.014","article-title":"A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases","volume":"139","author":"Khouri","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ejphar.2025.177820_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jad.2011.07.011","article-title":"Subjective recognition of adverse events with antidepressant in people with depression: a prospective study","volume":"135","author":"Kikuchi","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2025.177820_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat. Med."},{"key":"10.1016\/j.ejphar.2025.177820_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.ejphar.2025.177820_bib21","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2023.04.009","article-title":"Ventricular arrhythmias associated with over-the-counter and recreational opioids","volume":"81","author":"Krantz","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2025.177820_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00002018-200831020-00003","article-title":"Drug-induced ocular disorders","volume":"31","author":"Li","year":"2008","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177820_bib23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/IJN.S294807","article-title":"Progress of nanotechnology in diabetic retinopathy treatment","volume":"16","author":"Liu","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejphar.2025.177820_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/eye.2016.258","article-title":"Fingolimod: therapeutic mechanisms and ocular adverse effects","volume":"31","author":"Mandal","year":"2017","journal-title":"Eye (Lond. 1990)"},{"key":"10.1016\/j.ejphar.2025.177820_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/ICU.0000000000001063","article-title":"Ocular toxicities associated with antibody drug conjugates","volume":"35","author":"Marshall","year":"2024","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.ejphar.2025.177820_bib26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol. Therap."},{"key":"10.1016\/j.ejphar.2025.177820_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejphar.2025.177820_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1074248420984082","article-title":"Use of disproportionality analysis to identify previously unknown drug-associated causes of cardiac arrhythmias using the food and drug administration adverse event reporting system (FAERS) database","volume":"26","author":"Moreland-Head","year":"2021","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2025.177820_bib29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.17981","article-title":"Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review","volume":"36","author":"Neagu","year":"2022","journal-title":"JEADV, J. Eur. Acad. Dermatol. Venereol., Suppl."},{"key":"10.1016\/j.ejphar.2025.177820_bib30","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2174\/1381612822666161205110027","article-title":"The role of rho kinase inhibitors in corneal endothelial dysfunction","volume":"23","author":"Okumura","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2025.177820_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40264-019-00873-8","article-title":"Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"43","author":"Patek","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177820_bib32","article-title":"Dupilumab-associated blepharoconjunctivitis","volume":"16","author":"Paulose","year":"2019","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"10.1016\/j.ejphar.2025.177820_bib33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Roger","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.ejphar.2025.177820_bib34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1037\/bul0000102","article-title":"Gender differences in depression in representative national samples: meta-Analyses of diagnoses and symptoms","volume":"143","author":"Salk","year":"2017","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.ejphar.2025.177820_bib35","first-page":"75","article-title":"Ocular adverse effects associated with systemic medications : recognition and management","volume":"67","author":"Santaella","year":"2007","journal-title":"Drugs (Basel)"},{"key":"10.1016\/j.ejphar.2025.177820_bib36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3390\/cancers16020350","article-title":"Exploring the spectrum of VEGF inhibitors' toxicities from systemic to intra-vitreal usage in medical practice","volume":"16","author":"Santorsola","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.177820_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cells14050376","article-title":"Diabetic retinopathy (DR): mechanisms, current therapies, and emerging strategies","volume":"14","author":"Seo","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.177820_bib38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2025.177820_bib39","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/ICL.0000000000000601","article-title":"Clinical outcomes of lifitegrast 5% ophthalmic solution in the treatment of dry eye disease","volume":"46","author":"Tong","year":"2020","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.ejphar.2025.177820_bib40","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177820_bib41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(07)60198-6","article-title":"The eye in hypertension","volume":"369","author":"Wong","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177820_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/ceo.14454","article-title":"Drug-associated glaucoma: a real-world study based on the food and drug administration adverse event reporting system database","volume":"53","author":"Wu","year":"2025","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ejphar.2025.177820_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.13.9.17","article-title":"Drug-related keratitis: a real-world FDA adverse event reporting system database study","volume":"13","author":"Wu","year":"2024","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ejphar.2025.177820_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100104","article-title":"Real-world large sample assessment of drug-related dry eye risk: based on the FDA adverse event reporting system database","volume":"13","author":"Wu","year":"2024","journal-title":"Asia Pac .J. Ophthalmol. (Phila)"},{"key":"10.1016\/j.ejphar.2025.177820_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241285929","article-title":"Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database","volume":"15","author":"Wu","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177820_bib46","article-title":"Food and drug administration adverse event reports of diabetic retinopathy, macular edema and blurred vision associated with GLP-1 receptor agonist use","volume":"61","author":"Xiao","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejphar.2025.177820_bib47","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia (Cph.)"},{"key":"10.1016\/j.ejphar.2025.177820_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejphar.2025.177820_bib49","article-title":"Blurred vision","volume":"368","author":"Zhou","year":"2020","journal-title":"BMJ (Pract. Obs. Ed.)"},{"key":"10.1016\/j.ejphar.2025.177820_bib50","article-title":"Drug-induced fall risk in older patients: a pharmacovigilance study of FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925005746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925005746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:28:16Z","timestamp":1778876896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925005746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":50,"alternative-id":["S0014299925005746"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177820","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177820"}}